Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Meta‐Analysis

Guillaume Lefèvre(Université de Lille), David Launay(Inserm), É. Hachulla(Centre Hospitalier Universitaire de Lille), Luc Dauchet(Inserm), David Montani(Inserm), Marc Humbert(Inserm), Pierre‐Yves Hatron(Centre Oscar Lambret), M. Lambert(Hôpital Claude Huriez), Vincent Sobanski(Inserm)
Arthritis & Rheumatism
June 5, 2013
10.1002/art.38029
Cited by 269

Related Papers

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
|New England Journal of Medicine|2009|857
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis
|JAMA|2014|739
Pathologic assessment of vasculopathies in pulmonary hypertension
|Journal of the American College of Cardiology|2004|713